

Supplementary Materials

Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape

Table S1. Regional lymph node status and distant metastasis at the time of diagnosis of 5315 patients with metaplastic carcinoma of the breast from the Surveillance, Epidemiology, and End Results (SEER) database, 2000 - 2018.

Nodal Status (n = 5315)		Frequency (%)
Unknown		2823 (53.1%)
Known		2492 (46.9%)
When nodal status was known (n = 2492)		
Positive lymph nodes		551 (22.1%)
Negative lymph nodes		1941 (77.9%)
SEER Metastasis (n = 5315)		Frequency (%)
Unknown		2275 (42.7%)
Known		3040 (57.2%)
Where metastasis was known (n = 3040)		
No metastasis		2890 (95.1%)
Bone metastasis only		27 (0.9%)
Brain metastasis only		8 (0.3%)
Liver metastasis only		8 (0.3%)
Lung metastasis only		62 (2.0%)
Bone + Brain metastases		1 (0.03%)
Bone + Liver metastases		4 (0.1%)
Bone + Lung metastases		19 (0.6%)
Brain + Lung metastases		4 (0.1%)
Liver + Lung metastases		8 (0.3%)
Bone + Brain + Lung metastases		1 (0.03%)
Bone + Liver + Lung metastases		5 (0.1%)
Brain + Liver + Lung metastases		1 (0.03%)
Combined metastases to bone, brain, liver, and lungs		2 (0.06%)
Overall Metastasis by Location		
Location	Status known (%)	Frequency (%)
Bone	Unknown	2271 (42.7%)
	Known	3044 (57.3%)
Brain	Unknown	2268 (42.7%)
	Known	3047 (57.3%)
Liver	Unknown	2268 (42.7%)
	Known	3047 (57.3%)
Lung	Unknown	2270 (42.7%)
	Known	3045 (57.3%)

Table S2. Treatment characteristics of 5315 patients with metaplastic carcinoma of the breast from the Surveillance, Epidemiology, and End Results (SEER) database, 2000 - 2018.

Treatment (n = 5315)		Frequency (%)
Unknown		24 (0.5%)
Known		5291 (99.5%)
Where treatment status were known (n = 5291)		
No treatment		199 (3.8%)
Surgery only		1509 (28.5%)
Chemotherapy only		126 (2.4%)
Radiation only		6 (0.1%)
Surgery + Chemotherapy		1296 (24.5%)
Surgery + Radiation		574 (10.9%)
Chemotherapy + Radiation		11 (0.2%)

Combination therapy (Surgery + Chemotherapy + Radiation)	1568 (29.6%)
--	--------------

Table S3. Survival data of 5315 patients with Metaplastic carcinoma of the breast from the Surveillance, Epidemiology, and End Results (SEER) database, 2000 - 2018.

Survival	Overall Survival% (C.I. 95%)	Cause specific survival% (C.I. 95%)	Chemotherapy% (C.I. 95%)	Surgery% (C.I. 95%)	Radiation% (C.I. 95%)	Surgery + Chemotherapy (C.I. 95%)	Surgery + Radiation % (C.I. 95%)	Combined Chemotherapy, surgery, and Radiation (C.I. 95%)
1 year	88.4% (87.3-89.3)	90.1% (89.2-91.0)	92.2% (91.1-93.2)	92.7% (91.8-93.5)	96.0% (95.0-96.8)	93.9% (92.8-94.8)	96.1% (95.1-96.9)	96.8% (95.7-97.7)
2 years	77.9% (76.6-79.2)	81.4% (80.2-82.6)	82.7% (81.1-84.2)	84.1% (82.8-85.2)	89.1% (87.5-90.6)	84.5% (82.9-86.0)	89.4% (97.8-90.8)	89.2% (87.3-90.8)
3 years	71.4% (69.9-72.8)	76.2% (74.8-77.5)	77.6% (75.8-79.3)	78.8% (77.4-80.1)	83.6% (81.7-85.4)	79.4% (77.6-81.1)	83.9% (81.9-85.6)	83.3% (80.9-85.3)
4 years	67.1% (65.5-68.6)	73.1% (71.6-74.5)	74.3% (72.4-76.1)	75.7% (74.2-77.1)	80.5% (78.4-82.5)	76.3% (74.3-78.1)	80.8% (78.7-82.7)	79.8% (77.3-82.1)
5 years	63.6% (62.0-65.1)	71.1% (69.5-72.6)	72.6% (70.6-74.5)	73.6% (72.0-75.1)	78.7% (76.5-80.7)	74.5% (72.5-76.4)	79.0% (76.7-81.0)	78.1% (75.4-80.4)

Table S4. Survival by race data of 5315 patients with metaplastic carcinoma of the breast from the Surveillance, Epidemiology, and End Results (SEER) database, 2000 - 2018.

Survival	White% (C.I. 95%)	Black% (C.I. 95%)	Asian or Pacific Islander% (C.I. 95%)	American Indian or Alaska Native% (C.I. 95%)
1 year	90.3% (89.2-91.3)	88.8% (86.1-91.0)	91.6% (87.3-94.4)	85.0% (59.7-91.5)
2 years	82.3% (80.9-83.7)	76.4% (72.8-79.6)	83.9% (78.4-88.1)	69.1% (43.6-84.8)
3 years	77.6% (76.0-79.1)	69.2% (65.2-72.8)	77.1% (70.8-82.2)	69.1% (43.6-84.8)
4 years	74.3% (72.6-75.9)	65.9% (61.8-69.7)	76.5% (70.2-81.7)	69.1% (43.6-84.8)
5 years	72.4% (70.7-74.1)	63.2% (58.9-67.1)	75.2% (68.7-80.6)	63.3% (37.9-80.6)